Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UCHL5 | Q9Y5K5 | 2/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 15/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 15/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 15/20 | 0.50 |
| ▸ | HDAC7 | Q8WUI4 | 15/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 15/20 | 0.50 |
| ▸ | HDAC10 | Q969S8 | 15/20 | 0.50 |
| ▸ | HDAC11 | Q96DB2 | 15/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 15/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 15/20 | 0.50 |
| ▸ | HDAC9 | Q9UKV0 | 15/20 | 0.50 |
| ▸ | HDAC5 | Q9UQL6 | 15/20 | 0.50 |
| ▸ | TEK | Q02763 | 2/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.48 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.47 |
| ▸ | UCHL3 | P15374 | 1/20 | 0.47 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16155356 | 0.93 | HDAC3 (0.53) | UCHL5HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL16155169 | 0.92 | HDAC3 (0.54) | UCHL5HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL16155361 | 0.91 | HDAC3 (0.56) | UCHL5HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL16775813 | 0.83 | UCHL5 (0.44) | UCHL5HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL16155383 | 0.82 | UCHL5 (0.49) | UCHL5HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL16155382 | 0.79 | UCHL5 (0.46) | UCHL5HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL14987759 | 0.78 | TEK (0.55) | UCHL5HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL17601612 | 0.76 | UCHL5 (0.48) | UCHL5HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL30737267 | 0.76 | HDAC3 (0.48) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL460447 | 0.76 | TEK (0.55) | UCHL5HDAC3HDAC4HDAC1HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10590135-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2020-03-17 | — | — | US | disclosed |
| EP-2997029-B1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2019-01-09 | — | — | EP | disclosed |
| US-20180044338-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2018-02-15 | — | — | US | disclosed |
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2017-12-14 | — | — | US | disclosed |
| US-9834558-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2017-12-05 | — | — | US | disclosed |
| EP-3221312-A2 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | Glaxosmithkline LLC (US) | 2017-09-27 | — | — | EP | disclosed |
| US-9765075-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2017-09-19 | — | — | US | disclosed |
| WO-2016081692-A2 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2016-05-26 | — | — | WO | disclosed |
| EP-2997029-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | Glaxosmithkline LLC (US) | 2016-03-23 | — | — | EP | disclosed |
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
| WO-2014186313-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2014-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | UCHL5 538/4885HDAC3 70/4885HDAC4 125/4885 |
| US-20180044338-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | UCHL5 677/4885HDAC3 86/4885HDAC4 132/4885 |
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | UCHL5 538/4885HDAC3 70/4885HDAC4 125/4885 |
| US-10590135-B2 | Substituted bridged urea analogs as sirtuin modulators | SIRT1, SIRT3, SIRT2 | UCHL5 538/4885HDAC3 70/4885HDAC4 125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.